Skip to main content

Pharma/Regulatory

ACR20 Jefferson Memorial

ACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule

Feb 01, 2023

The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.



 The American College of Rheumatology (ACR) today submitted comments to Centers for Medicare and Medicaid

Read Article
hidradenitis.jpg

Hope for Biologic Treatment of Hidradenitis Suppurativa

Feb 01, 2023

A meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.



While only adalimumab is currently FDA approved

Read Article
shingles_0.jpg

Herpes Zoster with JAK Inhibitors

Jan 31, 2023

JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.

Read Article
hip.fx2_.jpg

Women at high risk of fracture remain untreated for osteoporosis

EurekAlert!
Jan 30, 2023

An estimated 100,000 to 120,000 fragility fractures occur annually in the Netherlands, the equivalent of at least 11 broken bones per hour. The cause is osteoporosis, a disease in which the skeleton becomes weak and fragile, leading to potentially devastating fractures that result in

Read Article
FDA oversees US drug sales, the largest single market for pharmaceuticals globally, worth an estimated $528 billion in 2020 in public and private spending (Figure 1). https://t.co/DMwoYIIyHP https://t.co/9nGStaotrO
JAK Janus

JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure?

Jan 23, 2023

Data from 17 international registries (JAK-pot collaboration) suggest that for Rheumatoid arthritis (RA) patients failing their first janus kinase inhibitor (JAKi), it did not matter if they were cycled to another JAKi or switched to a biologic disease-modifying antirheumatic drug (bDMARD).

Read Article
RheumNow Podcast square

PsA Til Death Do Us Part (1.20.2023)

Jan 20, 2023

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

Read Article
death

AS, but not PsA, has Increased Mortality Risk

Jan 19, 2023

Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease. A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA

Read Article
SPA.spectrum.jpg

Phase III Trials Back Bimekizumab for Spondyloarthritis

Medpage Today
Jan 19, 2023

Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.

Read Article
pso.PsA_.NPF_.jpg

Bimekizumab in Active Psoriatic Arthritis - BE COMPLETE study

Jan 11, 2023

BE COMPLETE is published, showing that bimekizumab (BMK), a selective dual inhibitor of interleukin (IL)-17F and IL-17A, results in superior improvement in both skin and joint outcomes in psoriatic arthritis (PsA) patients who have previously failed treatment with a tumour necrosis factor-α (

Read Article
Vertbral,Fracture,spine,compression

ACP Guidelines on Fracture Prevention in at-risk Adults

Jan 09, 2023

The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults. The full document and guideline can be found in the Annals of Internal Medicine. This guideline is the

Read Article
smoke.cannabis.hookah.weed_.jpg

Cannabis Use for Pain is Common

Jan 09, 2023

In states with legalized medical cannabis use, 3 in 10 persons are using cannabis to manage their pain.

Read Article
RheumNow Podcast square

2022 Rheumatology Year in Review (1-6-2023)

Jan 06, 2023

Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.

Read Article
2022,wordle

2022 Rheumatology Year in Review

Jan 05, 2023

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article
gout.podagra_0.jpg

Lubricin as a Treatment Target in Gout?

EurekAlert!
Jan 04, 2023

Many Americans think of gout as a disease from a bygone era, akin to rickets or scurvy. The condition commonly afflicted the rich and royal, including American historical figures such as Benjamin Franklin and Thomas Jefferson.



Gout is indeed one of the earliest known diseases, first

Read Article
cost.price_.drugs_.pills_.jpg

Drug Price Increases Continue in 2023

Jan 04, 2023

Reuters reports that in 2023, drug makers intend to increase the price of over 350 drugs.



Despite public outcry and goverment attempts to limit drug price increases (Biden's Inflation Reduction Act;IRA), these increases are expected to begin in January 2023.  The IRA is suppose to

Read Article
GCA,woman

In Giant Cell Arteritis, Hospital Admission Is Bad News

MedPage Today
Jan 03, 2023

One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.



Among the cohort of 1,206 patients hospitalized with

Read Article
OP_0.jpg

ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis

EurekAlert!
Jan 03, 2023

The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults. In the new guideline, ACP recommends bisphosphonates as initial pharmacologic treatment to reduce the risk of

Read Article
sit,sedentary,couch,coffee,comfort

Extreme Global Costs of Physical Inactivity

Jan 02, 2023

A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for non-communicable diseases (NCDs) and mental health conditions, it also imparts a considerable health and economic burden that is avoidable.

Read Article
renal.stone_.LBP_.jpg

Best of 2022: Allopurinol Safety in CKD Patients

Dec 30, 2022

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
computer screen safety

Best of 2022: Methotrexate Side Effects

Dec 28, 2022

Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of early RA patients starting methotrexate (MTX) shows that in the first year, adverse events (AE) were common, but not serious.

Read Article
GRAPPA,PsA,guideline

Best of 2022: New Updated GRAPPA Psoriatic Arthritis Recommendations

Dec 26, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
acne

Best of 2022: Acne with JAK Inhibitors

Dec 22, 2022

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi). Dermatologists often refer to this side effect as "

Read Article
ild.jpg

JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD

Dec 15, 2022

The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.



Overall the authors

Read Article
LiveVote.jpg

Substandard Therapy in Rheumatoid Arthritis

Medpage Today
Dec 13, 2022

Clinicians could improve outcomes in their patients with rheumatoid arthritis (RA) by paying attention to certain markers of care quality, such as early referral to certified rheumatologists and prescribing standard drugs for RA, new research suggested.

Read Article
×